196 related articles for article (PubMed ID: 23680636)
1. An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline.
Van Arnam EB; Blythe EE; Lester HA; Dougherty DA
Mol Pharmacol; 2013 Aug; 84(2):201-7. PubMed ID: 23680636
[TBL] [Abstract][Full Text] [Related]
2. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
Mihalak KB; Carroll FI; Luetje CW
Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
[TBL] [Abstract][Full Text] [Related]
3. Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.
Peng C; Stokes C; Mineur YS; Picciotto MR; Tian C; Eibl C; Tomassoli I; Guendisch D; Papke RL
J Pharmacol Exp Ther; 2013 Nov; 347(2):424-37. PubMed ID: 23959137
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic pharmacophore: the pyridine N of nicotine and carbonyl of acetylcholine hydrogen bond across a subunit interface to a backbone NH.
Blum AP; Lester HA; Dougherty DA
Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13206-11. PubMed ID: 20616056
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
[TBL] [Abstract][Full Text] [Related]
6. Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
Stokes C; Papke RL
Neuropharmacology; 2012 Sep; 63(4):538-46. PubMed ID: 22580377
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human α4β2 and α3β4 subtypes.
Arias HR; Feuerbach D; Targowska-Duda K; Kaczor AA; Poso A; Jozwiak K
Biochim Biophys Acta; 2015 Feb; 1848(2):731-41. PubMed ID: 25475645
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through study of ligand complexes with acetylcholine-binding protein.
Rucktooa P; Haseler CA; van Elk R; Smit AB; Gallagher T; Sixma TK
J Biol Chem; 2012 Jul; 287(28):23283-93. PubMed ID: 22553201
[TBL] [Abstract][Full Text] [Related]
9. Binding interactions with the complementary subunit of nicotinic receptors.
Blum AP; Van Arnam EB; German LA; Lester HA; Dougherty DA
J Biol Chem; 2013 Mar; 288(10):6991-7. PubMed ID: 23349463
[TBL] [Abstract][Full Text] [Related]
10. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
Smith JW; Mogg A; Tafi E; Peacey E; Pullar IA; Szekeres P; Tricklebank M
Psychopharmacology (Berl); 2007 Feb; 190(2):157-70. PubMed ID: 17115136
[TBL] [Abstract][Full Text] [Related]
11. Unique pharmacology of heteromeric α7β2 nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes.
Zwart R; Strotton M; Ching J; Astles PC; Sher E
Eur J Pharmacol; 2014 Mar; 726():77-86. PubMed ID: 24485886
[TBL] [Abstract][Full Text] [Related]
12. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
[TBL] [Abstract][Full Text] [Related]
13. Molecular actions of smoking cessation drugs at α4β2 nicotinic receptors defined in crystal structures of a homologous binding protein.
Billen B; Spurny R; Brams M; van Elk R; Valera-Kummer S; Yakel JL; Voets T; Bertrand D; Smit AB; Ulens C
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9173-8. PubMed ID: 22619328
[TBL] [Abstract][Full Text] [Related]
14. Using physical chemistry to differentiate nicotinic from cholinergic agonists at the nicotinic acetylcholine receptor.
Cashin AL; Petersson EJ; Lester HA; Dougherty DA
J Am Chem Soc; 2005 Jan; 127(1):350-6. PubMed ID: 15631485
[TBL] [Abstract][Full Text] [Related]
15. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
Spiller K; Xi ZX; Li X; Ashby CR; Callahan PM; Tehim A; Gardner EL
Neuropharmacology; 2009 Jul; 57(1):60-6. PubMed ID: 19393252
[TBL] [Abstract][Full Text] [Related]
16. The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.
Wildeboer-Andrud KM; Stevens KE
Pharmacol Biochem Behav; 2011 Nov; 100(1):17-24. PubMed ID: 21763340
[TBL] [Abstract][Full Text] [Related]
17. Importance of M2-M3 loop in governing properties of genistein at the α7 nicotinic acetylcholine receptor inferred from α7/5-HT3A chimera.
Grønlien JH; Ween H; Thorin-Hagene K; Cassar S; Li J; Briggs CA; Gopalakrishnan M; Malysz J
Eur J Pharmacol; 2010 Nov; 647(1-3):37-47. PubMed ID: 20816816
[TBL] [Abstract][Full Text] [Related]
18. The duplicated α7 subunits assemble and form functional nicotinic receptors with the full-length α7.
Wang Y; Xiao C; Indersmitten T; Freedman R; Leonard S; Lester HA
J Biol Chem; 2014 Sep; 289(38):26451-26463. PubMed ID: 25056953
[TBL] [Abstract][Full Text] [Related]
19. The binding orientation of epibatidine at α7 nACh receptors.
Thompson AJ; Metzger S; Lochner M; Ruepp MD
Neuropharmacology; 2017 Apr; 116():421-428. PubMed ID: 28089847
[TBL] [Abstract][Full Text] [Related]
20. Variations in binding among several agonists at two stoichiometries of the neuronal, α4β2 nicotinic receptor.
Tavares Xda S; Blum AP; Nakamura DT; Puskar NL; Shanata JA; Lester HA; Dougherty DA
J Am Chem Soc; 2012 Jul; 134(28):11474-80. PubMed ID: 22716019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
